Johnson & Johnson (JNJ)

• Market cap: $352B
• 1 day: -1.40%
• 5 days: -6.07%
• 1 month: -5.18%
• 3 months: -6.27%
• 6 months: -3.63%
• Year to date: 1.62%
• 1 year: -3.32%
• 5 years: -0.87%
• 10 years: 43.73%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Employees: 139,800

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

151% more first-time investments, than exits

New positions opened: 435 | Existing positions closed: 173

25% more call options, than puts

Call options by funds: $2.64B | Put options by funds: $2.11B

5% more funds holding

Funds holding: 3,832 [Q3] → 4,014 (+182) [Q4]

1.66% more ownership

Funds ownership: 70.16% [Q3] → 71.82% (+1.66%) [Q4]

6% less capital invested

Capital invested by funds: $273B [Q3] → $256B (-$16.5B) [Q4]

23% less funds holding in top 10

Funds holding in top 10: 189 [Q3] → 145 (-44) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 1,330 | Existing positions reduced: 1,910

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $153 5% upside
• Avg. target: $166 14% upside
• High target: $181 24% upside

7 analyst ratings

• positive: 3 43%
• neutral: 4 57%
• negative: 0 0%

Leerink Partners David Risinger 40% 1-year accuracy 4 / 10 met price target	5% upside $153	Market Perform Downgraded	13 May 2025
Barclays Matt Miksic 56% 1-year accuracy 22 / 39 met price target	13% upside $165	Equal-Weight Maintained	17 Apr 2025
Raymond James Jayson Bedford 62% 1-year accuracy 18 / 29 met price target	12% upside $164	Outperform Maintained	16 Apr 2025
Morgan Stanley Terence Flynn 36% 1-year accuracy 8 / 22 met price target	15% upside $169	Equal-Weight Maintained	16 Apr 2025
RBC Capital Shagun Singh 48% 1-year accuracy 33 / 69 met price target	24% upside $181	Outperform Reiterated	16 Apr 2025